Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD155/PVR drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD155 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View CD155 Products |
| Gene Delivery | CD155 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based binding assays. |
View CD155 Products |
| Benchmark Ab | Anti-CD155 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View CD155 Products |
| Validator | CD155 siRNA Set For knockdown verification in functional target validation assays. |
View CD155 Products |
| Related Target A | TIGIT Primary inhibitory receptor for CD155; key immune checkpoint partner in the TIGIT-CD155 axis. |
View TIGIT Products |
| Related Target B | CD96 Inhibitory receptor sharing the CD155 ligand; crucial for NK cell-mediated tumor surveillance. |
View CD96 Products |
| Related Target C | DNAM-1 (CD226) Activating receptor that competes with TIGIT/CD96 for CD155 binding; critical mediator of immune activation. |
View CD226 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Cynomolgus, and Mouse ortholog CD155 proteins available with >95% purity verified by SDS-PAGE. |
| Receptor competition profiling (TIGIT vs DNAM-1) | Sequence-verified, highly stable extracellular domains (ECD) with native post-translational modifications. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA sets included for target knockdown and specificity verification. |
Live CD155/PVR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD155/PVR therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific antibodies and antibody-drug conjugates (ADCs). As first-generation therapies targeting the TIGIT/CD155 axis reach advanced clinical trials, the next wave of R&D is targeting the selective blockade of CD155 to simultaneously inhibit TIGIT/CD96 signaling while preserving or enhancing DNAM-1-mediated costimulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | NextCure, Merck, GSK | Solid Tumors (NSCLC, Colorectal, Ovarian) | Epitope binning and competitive binding assays (Need high-purity CD155 ECD-Fc) |
| Bispecific / Multi-specifics | Roche, AstraZeneca | Advanced Malignancies, Immunotherapy resistant tumors | Simultaneous binding kinetics and stoichiometry validation (Need cross-reactive orthologs) |
| Cell Therapy (CAR-T/NK) | Academic Institutions, Biotech Startups | Hematological & Solid Tumors | Stable target-expressing cell line construction (Need CD155 Lentivirus for stable expression) |